Legal & General Group PLC Provention Bio, Inc. Transaction History

Legal & General Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.7 - $24.21 $78,972 - $285,363	11,787 Added 41.87%	39,941 $962,000
Q4 2022 Feb 14, 2023	BUY	$4.52 - $10.57 $32,286 - $75,501	7,143 Added 34.0%	28,154 $297,000
Q3 2022 Nov 14, 2022	SELL	$3.43 - $5.62 $49,169 - $80,562	-14,335 Reduced 40.56%	21,011 $95,000
Q2 2022 Aug 22, 2022	BUY	$3.65 - $7.3 $10,887 - $21,775	2,983 Added 9.22%	35,346 $141,000
Q4 2021 Feb 14, 2022	BUY	$5.59 - $7.39 $96,025 - $126,945	17,178 Added 113.12%	32,363 $182,000
Q3 2021 Nov 15, 2021	BUY	$5.66 - $8.33 $53,170 - $78,252	9,394 Added 162.22%	15,185 $97,000
Q2 2021 Aug 12, 2021	SELL	$6.71 - $11.04 $9,514 - $15,654	-1,418 Reduced 19.67%	5,791 $49,000
Q1 2021 May 17, 2021	BUY	$10.12 - $19.45 $1,011 - $1,945	100 Added 1.41%	7,209 $76,000
Q3 2020 Nov 13, 2020	SELL	$10.34 - $15.2 $13,504 - $19,851	-1,306 Reduced 15.52%	7,109 $91,000
Q2 2020 Aug 14, 2020	BUY	$7.81 - $17.0 $65,721 - $143,055	8,415 New	8,415 $119,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.